At the recent 2023 ASCO GI Cancers Symposium, researchers from the Royal College of Surgeons in Ireland (RCSI) presented results of a preclinical study that aimed to evaluate the potential of administering the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor ribociclib with the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib.
After a difficult start, there’s been more progress in PIK3 drug class, with FDA approval of Novartis AG’s Vijoice (alpelisib) for the rare condition PIK3CA-related overgrowth spectrum (PROS).
BEIJING – Shandong, China-based Luoxin Pharmaceuticals Group Stock Co. Ltd. said its PIK3α inhibitor, LX-086, has been approved by China’s National Medical Products Administration (NMPA) to enter clinical trials for advanced solid tumors.
BEIJING – Shandong, China-based Luoxin Pharmaceuticals Group Stock Co. Ltd. said its PIK3α inhibitor, LX-086, has been approved by China’s National Medical Products Administration (NMPA) to enter clinical trials for advanced solid tumors, two weeks after Novartis AG’s alpelisib, which aims at the same target, was also granted IND clearance in China.